Optimata Ltd.'s Virtual Patient Technology To Support Development Of Eli Lilly and Company Drug Candidate
Optimata Ltd. today announced the completion of the first phase of a pilot collaboration project with Eli Lilly & Co. The project utilizes Optimata's proprietary Virtual Patient Technology to assist in the clinical trial design of a novel anti-cancer cytotoxic compound.
In the course of the collaboration Optimata's researchers will use Optimata's proprietary virtual cancer patient software to evaluate pre-clinical data provided by Eli Lilly. Working hand-in-hand with Eli Lilly's staff, Optimata will suggest ways of optimizing the clinical drug development program through in-silico prediction of the expected response in humans.
"We are excited to have this opportunity to work with a leading pharmaceutical manufacturer like Eli Lilly," said Guy Malchi, President of Optimata.
Optimata’s virtual patient technology is based on a computer-generated method of accurately predicting how individual patients or patient populations will respond to a compound. The technology combines computer models of human physiology, specific diseases and the therapeutic impact of a compound. The technology forecasts the results of putative preclinical and clinical experiments at an unprecedented scale, allowing an unlimited number of “virtual trials” to be carried out on a wide range of dosages, treatment schedules and patient population characteristics.
The collaboration will draw upon Optimata’s biomathematical and disease modeling expertise which enables an accurate portrayal of the dynamics of disease processes and detailed predictions of drug effects. The collaboration will demonstrate how using Optimata’s Virtual Patient technology can aid in shortening clinical development time and provide guidance for focused clinical trials.
About Optimata
Optimata Ltd. is a science-based, interdisciplinary company, dedicated to the development of predictive biosimulation technologies – Virtual Patient Engines. Optimata offers a rational approach for the selection of patient populations and the optimization of drug scheduling and dosage. Optimata’s technology is based on a computer-generated method of accurately predicting how individual patients or patient populations will respond to a compound. The technology combines computer models of human physiology, specific diseases and the therapeutic impact of a compound. The in-silico technology enables drug developers to conduct experiments at an unprecedented scale, enabling an unlimited number of “virtual trials” to be carried out on an almost infinite combination of dosages, treatment schedules and patient population characteristics. The company is currently completing a bio-simulation clinical trial on individualized breast cancer therapy in collaboration with Nottingham City Hospital in the UK and Soroka University Medical Center in Israel.
For more information about Optimata visit www.optimata.com
Or contact:
Guy Malchi, President Optimata Ltd. 7 Abba Hillel Silver Street Ramat-Gan 52522 Israel info@optimata.com Tel: +972-3-7519226 Fax: +972-3-7519229